A study to assess the efficacy and safety of ON 01910.Na given by continuous intravenous infusion for 72 hours every other week in patients with a blood disease who have failed, or are resistant to, or intolerant to Azacitidine or Decitabine treatments. Estudio para evaluar la eficacia y seguridad de ON 01910.Na administrada por infusion intravenosa continua durante 72 horas todas las semanas en pacientes con enfermedad sanguinea que han fracasado, son resistente, o intolerantes a tratamientos con azacitidina o decitabina The primary objective of the study is to compare overall survival (OS) in patients receiving 1800 mg/24 hr of ON 01910.Na via 72-hour continuous intravenous infusion administered every other week + be...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study which compares Rigosertib with standard of care treatment in patients with ineffective production of blood cells (myelodysplastic syndrome) who have undergone treatment with azacitidine or decitabine without success The primary objective of this trial is: • to compare the overall survival (OS) of patients in the rigosertib group vs the Physician`s Choice group, in all patients and in a subgroup of patients wit...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to assess the efficacy and safety of rigosertib given by continuous intravenous infusion for 72 hours in patients with a blood disease called myelodysplastic syndrome who have failed azacitidine or decitabine treatments Estudio para determinar la eficacia y seguridad de rigosertib administrado en forma de perfusiones intravenosas continuas de 72 horas en pacientes con síndrome mielodisplásico con fallo de tratamiento con azacitidina o decitabina The primary efficacy objective of the study is to evaluate the relationship between best bone marrow blast response and overall survival in MDS patients with excess blasts (5-30%) progressing on or af...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to assess the efficacy and safety of oral rigosertib in patients with myelodysplastic syndrome (a blood disease) who are dependent on transfusions The primary efficacy objective is to determine the onset of hematological improvement according to the 2006 International Working Group (IWG) criteria.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune